Clinical trials: HIV Risk Reduction

HIV Infections, Dyslipidemias

Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)

• Terminated
• Age: 50 years and older
• Phase 2
• Results posted

This is a phase 2, randomized, double-blinded, placebo-controlled clinical trial. The intervention drug will be efprezimod alfa (intravenous [IV] infusion).

Trial name

CALIBER (NCT03960541)

Testing

Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution

Where

United States

Volunteers

8 people

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)